Avalyn Pharma Inc. Common Stock
AVLN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.14B
Close$
$1.21
95.6% downside
Current Fair Value
95.6% downsideOvervalued by 95.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.14 Billion |
|---|---|
| Enterprise Value | $889.17 Million |
| Earnings per Share | $-2.04 |
| Beta | -1.13 |
| Outstanding Shares | 44,333,094 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -19.87 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 3.43 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.60
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.71
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.06%▼ 106.30% |
|---|---|
| Total Invested | $791,746▼ 99.95% |
| Investors Holding | 5▼ 90.00% |
About Avalyn Pharma Inc. Common Stock
50 employees
CEO: Lyn Baranowski
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis ...